249 related articles for article (PubMed ID: 1820757)
1. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
2. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
4. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
Hollander E; DeCaria CM; Schneier FR; Schneier HA; Liebowitz MR; Klein DF
J Clin Psychiatry; 1990 Mar; 51(3):119-23. PubMed ID: 2106515
[TBL] [Abstract][Full Text] [Related]
5. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
6. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
Pigott TA; Pato MT; L'Heureux F; Hill JL; Grover GN; Bernstein SE; Murphy DL
J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
9. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
[TBL] [Abstract][Full Text] [Related]
12. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
Servant D; Bailly D; Le Seac'h H; Parquet PJ
Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
[TBL] [Abstract][Full Text] [Related]
13. Fluvoxamine treatment of obsessive-compulsive disorder.
Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
Goodman WK; Price LH; Rasmussen SA; Delgado PL; Heninger GR; Charney DS
Arch Gen Psychiatry; 1989 Jan; 46(1):36-44. PubMed ID: 2491940
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Price LH; Delgado PL; Krystal JH; Charney DS; Heninger GR
Am J Psychiatry; 1990 May; 147(5):652-4. PubMed ID: 1970224
[TBL] [Abstract][Full Text] [Related]
16. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
17. Treatment of depersonalization with serotonin reuptake blockers.
Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
20. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
